Vivos Therapeutics (VVOS) Analyst Estimates Annual - Discounting Cash Flows
Vivos Therapeutics, Inc.
VVOS (NASDAQ)

* (except for per share items) of USD
Period Ending: 2025
12-31
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
Number of Analysts 1 1 1 1 1 1
Estimated Revenue
Low 18.7 14.9 13.7 16.3 17.3 12.9
Average 19.2 15.2 14.0 16.5 17.3 12.9
High 19.6 15.5 14.3 16.8 17.3 12.9
Estimated EBITDA
Low -18.5 -14.7 -13.5 -15.9 -16.3 -12.2
Average -18.1 -14.4 -13.2 -15.6 -16.3 -12.2
High -17.7 -14.0 -12.9 -15.4 -16.3 -12.2
Estimated EBIT
Low -19.0 -15.1 -13.9 -16.3 -16.8 -12.5
Average -18.6 -14.7 -13.6 -16.0 -16.8 -12.5
High -18.1 -14.4 -13.2 -15.8 -16.8 -12.5
Estimated Net Income
Low -1.34 -2.54 -13.2 -33.0 -27.4 -18.3
Average -1.30 -2.46 -12.8 -32.3 -27.4 -18.3
High -1.26 -2.39 -12.4 -31.6 -27.4 -18.3
Estimated SGA Expenses
Low 33.1 26.2 24.1 28.8 30.6 22.9
Average 33.8 26.9 24.7 29.2 30.6 22.9
High 34.6 27.5 25.3 29.7 30.6 22.9
Estimated EPS
Low -1.097 -2.080 -10.83 -27.06 -22.50 -15.00
Average -1.065 -2.020 -10.52 -26.50 -22.50 -15.00
High -1.033 -1.960 -10.20 -25.94 -22.50 -15.00
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us